Major Companies in India Psychosis Market | Insights & Key Players 2026

India Psychosis Market Overview

According to 6Wresearch, the India psychosis market is witnessing steady growth driven by increasing awareness of mental health conditions such as schizophrenia and bipolar disorder along with rising diagnosis rates and better access to psychiatric care. The growth of the healthcare infrastructure and supportive government initiatives like the National Mental Health Programme are further fueling the market. The demand for antipsychotic medications is increasing in urban and smaller cities, while companies are working to develop safer and more effective treatments, thereby strengthening India's position in global mental healthcare.

Competitive Landscape

The competitive landscape in the India psychosis market is a mix of domestic pharmaceutical leaders and global innovators. These companies are providing market depth through a wide portfolio of antipsychotic medications, long-acting injectables, and supportive therapies for chronic psychiatric disorders.

Leading Players Operating in the India Psychosis Market:

1. Sun Pharmaceutical Industries Ltd.

The largest player in India's psychiatric segment, Sun Pharma provides sophisticated therapies like Quetiapine (Qutipin) and Olanzapine, handling complex compliance and large-scale distribution to mental health clinics.

2. Torrent Pharmaceuticals Ltd.

A major force in the CNS space, Torrent focuses on chronic therapy compliance and high-precision medications for schizophrenia, often ranking among the top three players in neuropsychiatry.

3. Intas Pharmaceuticals Ltd.

A historic innovator in tech-heavy formulations, Intas is renowned for its specialized antipsychotic portfolio, including brands like Qutan and Mozep, tailored for diverse psychiatric needs.

4. Cipla Limited

A global giant in the specialty segment, Cipla provides an end-to-end CNS management suite, integrating medication with patient-centric support platforms for long-term health management.

5. Lupin Limited

Caters to the modern healthcare workforce with an integrated platform that emphasizes transparency in drug processing and specialized solutions for neuropsychiatric patients.

6. Zydus Lifesciences Ltd.

Combines pharmaceutical excellence with clinical automation, offering specialized antipsychotics such as Elicia (Blonanserin) to administrative psychiatric teams and large-scale hospitals.

7. Alkem Laboratories Ltd.

A top-tier platform in the CNS segment, Alkem leverages advanced manufacturing data to provide high-precision dosages for schizophrenia and bipolar disorder across diverse industries.

8. Dr. Reddy's Laboratories

Part of the global tech-pharma ecosystem, this brand focuses on providing affordable, highly customizable generic tools integrated with broad antipsychotic applications.

9. Mankind Pharma Ltd.

Leverages decades of experience to provide technology-enabled system processing and high-volume distribution of essential psychiatric medications for the Indian masses.

10. La Renon Healthcare Pvt Ltd.

Provides specialized CNS solutions and workforce management tools, supporting some of the largest private psychiatric networks in the country with niche molecules.

11. Abbott India Limited

Specializes in managed systems and high-quality CNS audits, delivering reliable care for complex psychotic conditions through globally recognized therapeutic frameworks.

12. Micro Labs Limited

A global pioneer in the CNS segment, Micro Labs provides sophisticated tablet and liquid solutions that handle the complex needs of mental health management.

13. Ipca Laboratories Ltd.

A major force in the global space, Ipca focuses on multi-country compliance and provides high-precision antipsychotic tools for large-scale corporations and health systems.